Viraplacel
Viraplacel
Mesenchymal stem cell (MSC) therapy is one of the most innovative modern medical approaches for controlling and preventing graft-versus-host disease (GVHD) in cancer patients following bone marrow transplantation.
Product Specifications
- Reduced risk of graft-versus-host disease (GVHD):
By modulating the immune response and suppressing inflammation, it prevents severe immune reactions. - Anti-inflammatory and immune-modulating properties:
- Secretion of anti-inflammatory factors leads to a reduction in systemic inflammation.
- High safety profile with minimal side effects:
Unlike conventional immunosuppressive drugs, it has a targeted effect without broad suppression of the immune system. - Unlike conventional immunosuppressive drugs, it has a targeted effect without broad suppression of the immune system.
Unlike conventional immunosuppressive drugs, it has a targeted effect without broad suppression of the immune system.
Viraplacel
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.